1. Home
  2. GOSS

as 09-05-2025 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Founded: 2015 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 586.6M IPO Year: 2019
Target Price: $8.50 AVG Volume (30 days): 3.3M
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.61 EPS Growth: N/A
52 Week Low/High: $0.66 - $2.98 Next Earning Date: 11-06-2025
Revenue: $40,237,000 Revenue Growth: -58.02%
Revenue Growth (this year): -68.31% Revenue Growth (next year): 30.65%

GOSS Daily Stock ML Predictions

Stock Insider Trading Activity of Gossamer Bio Inc. (GOSS)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Milligan Sandra GOSS N/A Aug 19 '25 Buy $1.92 26,050 $50,016.00 58,050

Share on Social Networks: